Kazia Therapeuticsの本社所在地
Kazia Therapeuticsの本社所在地は何ですか。
Kazia Therapeutics Limitedの本社所在地はAustraliaです。
本社所在地の定義は何ですか。
会社の本社所在地 。
Foreign companies can be traded on US stock markets and vice-versa. Obligation of foreign companies traded on US exchanges might slightly differ from obligations of domestic companies.
Kazia Therapeuticsは何をしますか。
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.